IRIS
FANIN, Renato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.524
AS - Asia 8.769
EU - Europa 6.769
SA - Sud America 1.877
AF - Africa 168
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 9
Totale 42.136
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.222
SG - Singapore 4.156
UA - Ucraina 2.115
CN - Cina 2.030
BR - Brasile 1.551
DE - Germania 1.086
HK - Hong Kong 1.032
IT - Italia 745
FI - Finlandia 707
RU - Federazione Russa 579
VN - Vietnam 568
SE - Svezia 504
IE - Irlanda 380
CA - Canada 210
GB - Regno Unito 206
TR - Turchia 204
KR - Corea 165
IN - India 160
AR - Argentina 125
FR - Francia 116
BD - Bangladesh 72
IQ - Iraq 63
ZA - Sudafrica 62
PL - Polonia 61
MX - Messico 59
CO - Colombia 51
EC - Ecuador 46
ID - Indonesia 43
IR - Iran 43
AT - Austria 42
JP - Giappone 39
NL - Olanda 35
CZ - Repubblica Ceca 34
ES - Italia 31
UZ - Uzbekistan 28
BE - Belgio 24
PY - Paraguay 23
PK - Pakistan 21
PE - Perù 20
TG - Togo 20
VE - Venezuela 19
AE - Emirati Arabi Uniti 18
EU - Europa 18
MA - Marocco 18
SA - Arabia Saudita 18
EG - Egitto 16
CL - Cile 15
RO - Romania 15
UY - Uruguay 15
IL - Israele 13
GR - Grecia 12
KE - Kenya 11
KZ - Kazakistan 11
BO - Bolivia 10
JO - Giordania 10
LT - Lituania 10
RS - Serbia 10
AU - Australia 8
CH - Svizzera 8
KG - Kirghizistan 8
LV - Lettonia 8
NP - Nepal 8
OM - Oman 8
TN - Tunisia 8
AZ - Azerbaigian 7
BG - Bulgaria 7
DO - Repubblica Dominicana 7
DZ - Algeria 7
LB - Libano 6
TT - Trinidad e Tobago 6
AL - Albania 5
HU - Ungheria 5
JM - Giamaica 5
LK - Sri Lanka 5
AO - Angola 4
BH - Bahrain 4
GA - Gabon 4
HN - Honduras 4
LU - Lussemburgo 4
PA - Panama 4
PS - Palestinian Territory 4
TH - Thailandia 4
ET - Etiopia 3
GE - Georgia 3
HR - Croazia 3
KH - Cambogia 3
MY - Malesia 3
NO - Norvegia 3
RW - Ruanda 3
BN - Brunei Darussalam 2
BY - Bielorussia 2
CR - Costa Rica 2
CV - Capo Verde 2
EE - Estonia 2
KW - Kuwait 2
ML - Mali 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
Totale 42.108
Salva come PNG Salva come JPEG
Città #
Fairfield 2.992
Woodbridge 2.894
Houston 1.986
Ann Arbor 1.893
Ashburn 1.750
Singapore 1.549
Jacksonville 1.415
Seattle 1.224
Wilmington 1.129
Beijing 1.120
Chandler 1.109
Hong Kong 1.031
Cambridge 981
Dearborn 890
Boardman 485
Princeton 382
Dublin 377
Dallas 364
Udine 280
Los Angeles 267
Buffalo 192
San Diego 188
Ho Chi Minh City 187
Hefei 177
Izmir 169
Seoul 151
São Paulo 143
Munich 129
New York 125
Redondo Beach 111
Hanoi 99
Ogden 99
Ottawa 98
Norwalk 86
Dong Ket 84
Des Moines 78
Santa Clara 77
Trieste 60
Nanjing 55
Turku 55
Warsaw 55
Montreal 50
Redmond 50
Mumbai 48
Rio de Janeiro 45
Kunming 41
Milan 39
Phoenix 39
Toronto 37
Frankfurt am Main 36
Nuremberg 36
Tokyo 33
Belo Horizonte 32
Guangzhou 32
Stockholm 31
London 30
Regensburg 29
Simi Valley 29
Helsinki 28
Johannesburg 28
Tashkent 27
Atlanta 26
Boston 26
Brasília 24
Brussels 24
Chennai 24
Curitiba 24
Denver 24
Jinan 24
Hangzhou 23
Nanchang 23
Poplar 23
Haiphong 22
Chicago 21
Porto Alegre 21
Saint Petersburg 21
Baghdad 20
Düsseldorf 20
Leawood 20
Vienna 20
Da Nang 19
Guayaquil 19
Lomé 19
Orem 19
Campinas 18
Grafing 18
Mexico City 18
Ankara 17
Dhaka 17
Shenyang 17
Brooklyn 16
Manchester 16
Quito 16
Salvador 16
Bogotá 15
Rome 15
Venezia 15
Amsterdam 14
Chengdu 14
Fuzhou 14
Totale 28.018
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 270
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party 221
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 213
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 193
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 186
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 185
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 184
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 183
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 182
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 181
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 180
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 179
Atypical haemolytic-uraemic syndrome at the onset of acute promyelocytic leukaemia. 178
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 176
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 176
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 174
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 173
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 170
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 168
Multipotent Progenitor Cells Are Present in Human Peripheral Blood. 168
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 167
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 164
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 164
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 163
P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells 163
Management of immune thrombocytopenia in elderly patients 160
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 159
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 158
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 156
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 156
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 156
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 156
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 155
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 155
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 155
P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. 154
A comparison of allografting with autografting for newly diagnosed myeloma 154
Family history of cancer and risk of second malignancies in young cancer patients in Trieste, Italy. 153
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 153
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 152
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study 152
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 151
Autologus stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome. 150
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 150
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 150
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 150
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 150
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. 148
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 147
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 146
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. 146
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 146
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 145
Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo). 145
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 145
Rituximab for the treatment of type II mixed cryoglobulinemia. 144
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 144
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 143
“Overexpression of multidrug resistance-associated P-170 glycoprotein in acute non lymphocytic leukemia”. 142
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. 142
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 142
Multipotent Mesenchymal Stem Cells Can Be Isolated and Grown from Many Tissues (Bone Marrow, Liver and Heart) 142
Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. 141
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 141
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 141
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 141
Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience 141
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 140
Autologous stem cell transplantation in chronic carriers of hepatitis B virus and hepatitis C virus affected by onco-hematologic diseases. 140
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. 139
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. 139
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 139
Longitudinal follow-up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogeneic bone marrow transplant 138
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. 138
Late onset cytomegalovirus encephalitis after reduced-intensity conditioning allogeneic SCT: an emerging neurological complication? 138
Unexpected phenotype of a typical NPM1 mutant 138
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 138
Granulocyte-macrophage colony -stimulating factor in acute nonlymphocytic leukemia before and after chemo therapy”. 137
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 137
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 137
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT 137
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 136
Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia. 136
Pre-Chemotherapy risk factors for invasive fungal diseases: Prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (seifem 2010-a multicenter study) 136
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases 135
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation 135
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 134
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 134
Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases 134
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 133
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 133
Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. 132
The role of Rituximab in the therapy of mixed cryoglobulinemia 132
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. 132
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 131
Multidrug resistance modulation in vivo. The effect of cyclosporin alone or with dextro-verapamil on idarubicin pharmacokinetics in acute leukemia 131
Antibody binding capacity for evaluation of MDR-related proteins in acute promyelocytic leukemia: Onset versus relapse expression 131
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 130
Acute promyelocytic leucemia: low expression of multidrug resistance phenotype at onset suggest a favourable effect of gentuzumab ozogamicyn (CMA-676 129
The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia. 129
Totale 15.276
Salva come PNG Salva come JPEG
Categoria #
all - tutte 163.059
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 163.059
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.290 0 0 0 0 0 617 356 600 644 183 596 294
2021/20223.100 117 364 156 225 93 144 185 143 56 507 634 476
2022/20232.817 419 159 31 328 259 829 14 207 384 37 86 64
2023/2024853 122 66 27 27 132 100 17 53 142 65 32 70
2024/20256.868 149 502 381 170 292 309 407 426 665 603 1.093 1.871
2025/20267.094 1.008 1.468 1.119 1.335 1.865 299 0 0 0 0 0 0
Totale 43.192